<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05066672</url>
  </required_header>
  <id_info>
    <org_study_id>NAV-17A-007</org_study_id>
    <secondary_id>SPN820</secondary_id>
    <nct_id>NCT05066672</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-5138 in Adults With Treatment Resistant Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Navitor Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Supernus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Navitor Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of NV-5138 in adults with TRD&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The is a multicenter, randomized, double-blind, flexible- dose, placebo-controlled, parallel&#xD;
      design of adjunctive NV-5138 in adults with TRD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, double-blind, placebo-controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>matched placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the efficacy of NV-5138 as measured by the Montgomery-Asberg Depression Rating scale</measure>
    <time_frame>5 weeks</time_frame>
    <description>Change from Baseline to end of treatment period on the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score. MADRS captures a clinician-rated score on a seven-point Likert scale for a score ranging from 0 to 60, with higher scores reflecting greater depression severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the efficacy as measured by Clinical Global Impression-Severity (CGI-s) score</measure>
    <time_frame>5 weeks</time_frame>
    <description>Change from baseline to end of treatment period on the Clinical Global Impression-Severity score for NV-5138 treated patients as compared to placebo. The CGI-S is a clinican-rated seven point scale from 0-7 where a higher rating represents higher severity of illness.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <arm_group>
    <arm_group_label>NV-5138 400 mg oral capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Either 2 or 4 400 mg oral capsules administered once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>matched placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 or 4 oral capsules administered once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NV-5138</intervention_name>
    <description>NV-5138 is a novel, orally bioavailable, selective, direct activator of mTORC1 cellular signaling</description>
    <arm_group_label>NV-5138 400 mg oral capsules</arm_group_label>
    <other_name>SPN820</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>matched placebo</intervention_name>
    <description>matched placebo oral capsules</description>
    <arm_group_label>matched placebo</arm_group_label>
    <other_name>placebo</other_name>
    <other_name>PBO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, aged 18 to 70 years at Screening.&#xD;
&#xD;
          -  Diagnosis of Major Depressive Disorder (MDD) according to the Diagnostic and&#xD;
             Statistical Manual of Mental Disorders, 5th Edition (DSM-5) for either recurrent or&#xD;
             single episode MDD without psychotic features that is confirmed by the Mini&#xD;
             International Neuropsychiatric Interview (MINI).&#xD;
&#xD;
          -  Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of ≥26 for the current&#xD;
             MDE at all Screening visits and Baseline (Day 1).&#xD;
&#xD;
          -  CGI-S score of ≥4 (moderately ill or worse) at all Screening visits and Baseline.&#xD;
&#xD;
          -  History of inadequate response to ≥2 but ≤4 prior ADT therapies (including the current&#xD;
             ADT for the current MDE) ≥ 2 weeks at Screening and ≥ 8 weeks at Baseline.&#xD;
&#xD;
          -  Stable therapeutic dose of one of the following ADTs for the current MDE for ≥2 weeks&#xD;
             prior to Screening and maintain the therapeutic dose throughout the study: citalopram,&#xD;
             escitalopram, paroxetine, fluoxetine, sertraline, duloxetine, venlafaxine (IR or XR),&#xD;
             desvenlafaxine, or vortioxetine.&#xD;
&#xD;
          -  Detectable blood level of the approved ADT at Visits 1 and 2 of the Screening Period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  MADRS Total Score improvement of ≥25% from the highest to the lowest score at any&#xD;
             visit during the Screening Period.&#xD;
&#xD;
          -  Clinically significant abnormal laboratory profiles, vital signs, or&#xD;
             electrocardiograms (ECGs), per Investigator judgment.&#xD;
&#xD;
          -  Judged by the Investigator to be at significant risk for suicide, violence, or&#xD;
             homicide; or answers 'Yes' to items 4 or 5 on the Suicidal Ideation section of the&#xD;
             C-SSRS at Screening or at Baseline; or has attempted suicide within the 6 months prior&#xD;
             to Screening.&#xD;
&#xD;
          -  History of psychotic disorder, including but not limited to schizophrenia, MDD with&#xD;
             psychotic features, or bipolar I/II disorder with psychotic features.&#xD;
&#xD;
          -  History of PTSD, OCD, panic disorder, intellectual disability, autism, acute stress&#xD;
             disorder, or Cluster A or B personality disorder (per DSM-5 criteria).&#xD;
&#xD;
          -  Any condition or procedure that may interfere with the absorption, metabolism, or&#xD;
             elimination of the study medication (e.g., cholecystectomy or gastric bypass).&#xD;
&#xD;
          -  In the Investigator's opinion, is unlikely to comply with the protocol or is&#xD;
             unsuitable for any other reason.&#xD;
&#xD;
          -  History of alcohol and/or substance use disorder within 6 months prior to Screening or&#xD;
             is currently using or has positive results at Screening for drugs of abuse or has a&#xD;
             positive alcohol result at any Screening or Baseline visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randy Owen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Monitor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samuel Schaffer, MD</last_name>
    <phone>240-403-5758</phone>
    <email>samuel.schaffer@premier-research.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>September 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

